Pharmaceutical

Ultragenyx receives complete response letter for UX111 BLA

Ultragenyx Pharmaceutical has received a complete response letter (CRL) from the FDA concerning its BLA for UX111 (ABO-102).

Jul 15, 2025 - 06:00
Ultragenyx receives complete response letter for UX111 BLA
Ultragenyx Pharmaceutical has received a complete response letter (CRL) from the FDA concerning its BLA for UX111 (ABO-102).
Read the original article

Tags:

Previous Article

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Next Article

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Funding drought: how can biotech and biopharma keep trials running?

Funding drought: how can biotech and biopharma keep tri...

Mar 23, 2025

AstraZeneca wins approval for Imfinzi in NSCLC perioperative setting

AstraZeneca wins approval for Imfinzi in NSCLC perioper...

Aug 17, 2024

STAT+: Amputees have better balance, less pain after electrical stimulation, study finds

STAT+: Amputees have better balance, less pain after el...

Dec 15, 2023